NCT07223138Phase 3Enrolling by invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Study sponsor: MoonLake Immunotherapeutics AG

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-02-04Estimated

Enrollment · participants1560Estimated

Source updated2026-09-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-19 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Enrolling by invitation

Check registry source

Study details

Conditions studied

Arthritis, Psoriatic

Treatments or interventions studied

SonelokimabDrug

Primary outcomes · main study measures

Read the study measures

measure: Long-term safety and tolerability of sonelokimab:; description: Treatment-emergent adverse events (TEAEs); timeFrame: 52 weeks; measure: Long-term safety and tolerability of sonelokimab:; description: Serious adverse events (SAEs); timeFrame: 52 weeks; measure: Long-term safety and tolerability of sonelokimab:; description: TEAEs leading to study withdrawal; timeFrame: 52 weeks; measure: Long-term safety and tolerability of sonelokimab:; description: Adverse events of special interest (AESIs); timeFrame: 52 weeks; measure: Long-term safety and tolerability of sonelokimab:; description: Clinically significant changes in vital signs and standard 12-lead electrocardiogram Measure description: Number of participants with clinically significant changes in vital signs and 12-lead ECG intervals from baseline; timeFrame: 52 weeks; measure: Long-term safety and tolerability of sonelokimab:; description: Clinically significant changes in clinical laboratory parameters Measure description: Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline; timeFrame: 52 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history